Ryoncil is part of a development programme for inflammatory diseases such as SR-aGvHD in adults, and biologic-res ...

More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

Mesoblast's Ryoncil is now FDA-approved for pediatric SR-aGvHD, marking a milestone in mesenchymal stromal cell therapies in ...

The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...

Mesoblast announces that the FDA approved Ryoncil. Ryoncil is the only approved therapy for steroid-refractory acute graft ...

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft ...

Mesoblast (ASX:MSB) has received approval from the US Food and Drug Administration (FDA) for Ryoncil (remestemcel-L), making ...

Mesoblast Limited (AU:MSB) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ranked ...

Mesoblast shareholders are sitting on as much as 10-fold gains for the year, after the US Food and Drug Administration ...